Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of  patients with elevated LDL-C.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 12:30 PM ET on May 25, 2016
Last Price Change Open Day High 52-Week High
0.13  up   (0.851%) 15.35 15.75 109.24
Volume Previous Close Day Low 52-Week Low
141,888 15.28 15.05 12.61

View all »   RSSRecent Releases

May 4, 2016
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results

Mar 8, 2016
Esperion Therapeutics to Present at the Barclays Global Healthcare Conference